固形臓器およびHCT後のCMV再活性化または感染を治療するためのハプロ同一ドナーCMV特異的CTL
固形臓器および造血幹細胞移植(HCT)後のCMV再活性化または感染を治療するためのハプロ同一ドナーサイトメガロウイルス(CMV)特異的細胞傷害性Tリンパ球(CTL)のパイロット研究
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy.
OUTLINE:Patients are assigned to 1 of 2 Cohorts.
COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial.
COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial.
After completion of study treatment, participants are followed up at 1 year.
研究の種類
入学 (推定)
段階
- 初期フェーズ 1
連絡先と場所
研究連絡先
- 名前:The Ohio State University Comprehensive Cancer Center
- 電話番号:800-293-5066
- メール:OSUCCCClinicaltrials@osumc.edu
研究連絡先のバックアップ
- 名前:Nicole Szuminski
- 電話番号:614-688-9796
- メール:Nicole.Szuminski@osumc.edu
研究場所
-
-
Ohio
-
Columbus、Ohio、アメリカ、43205
- 募集
- Nationwide Children's Hospital
-
コンタクト:
- Chris Ouellette, MD
-
コンタクト:
- Melinda Triplet, RN, BSN
- 電話番号:614-722-6039
- メール:Melinda.Triplet@nationwidechildrens.org
-
Columbus、Ohio、アメリカ、43210
- 一時停止
- Ohio State University Comprehensive Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have solid organ transplant or have received allogeneic hematopoietic stem cell transplant.
-
• Cohort A (CMV): Must have documented CMV disease or reactivation, as by:
-
Viremia as detected by quantitative polymerase chain reaction (PCR) (> 500 IU/ml) in the peripheral blood requiring treatment OR
-
High risk for antiviral failure due to history of recurrent CMV reactivations or evidence of antiviral drug resistance, OR
-
Unable to tolerate antiviral drugs due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
• Cohort B (AdV): Must have documented AdV infection or reactivation, as by:
-
Symptomatic subject with any detectable viral load in blood, OR
-
Symptomatic subject with qualitative AdV detection in compartment of current symptomatology, including stool, urine, and/or other specimens (bronchoalveolar lavage (BAL), nasal swab, CSF, etc.), irrespective of blood viral load, OR
-
New, persistent, and/or worsening AdV-related symptoms, signs, and/or markers of end organ compromise while receiving antiviral therapy (ie cidofovir), OR
-
Asymptomatic with a viral load > 1000 copies/ml in peripheral blood, OR
-
Unable to tolerate antiviral treatment due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
- Karnofsky (age > 16 years) or Lansky performance score > 70 (age < 16)
- Available seropositive haploidentical or matched donor who is without evidence of infection that would otherwise preclude donation
- Negative pregnancy test in female patients if applicable (childbearing potential, has not received a full-intensity conditioning regimen
- Written informed consent and/or signed assent line from patient, parent or guardian
- DONOR
- Human leukocyte antigen (HLA)-haploidentical or full-match to the patient as determined by institutional standards
- Cohort A: CMV seropositive, defined as detection of serum CMV immunoglobulin G (IgG)
- Cohort B: AdV seropositive, defined as detection of serum AdV IgG
- Age 18 or over
- Meet donor eligibility or suitability according to institutional standards. If the donor is deemed ineligible according to Foundation for the Accreditation of Cellular Therapy (FACT) standards, but is suitable for donation per institutional standards, the donor will be eligible for the protocol
-
Exclusion Criteria:
-
Receipt of anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell depleting agents within 21 days of screening for enrollment.
-
Receipt of > 0.5mg/kg/day of prednisone or steroid equivalent at the time of enrollment. Stable GVHD is permitted as long as patients are on stable dose steroids of less than or equal to 0.5 mg/kg/day of prednisone or steroid equivalent.
-
Evidence of uncontrolled infection as follows:
- Bacterial infections - patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.
- Fungal infections - patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.
- Patients with hemodynamic instability attributable to bacterial sepsis or new symptoms, worsening physical signs or radiographic findings attributable to concomitant bacterial or fungal infection are excluded. Patients who require ventilator support for CMV pneumonitis are not excluded. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
-
Receipt of donor lymphocyte infusion (DLI) within 28 days.
-
Patients with active acute graft versus host disease (GvHD) grades II-IV requiring > 0.5 mg/kg/day of prednisone or steroid equivalent or T-cell depleting immunosuppression.
-
Acute graft rejection in solid organ transplantation requiring augmented immunosuppression with T-cell depleting agents or steroids as mentioned above.
-
Active and uncontrolled relapse of malignancy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (CMV-specific CTLs)
Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
|
実験的:Treatment (AdV-specific CTLs)
Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
実現可能性は、4 週間以内に適切なドナーを特定し、最終製品で最小 T 細胞用量を満たすこととして定義されます
時間枠:最長1年
|
最長1年
|
|
|
Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0
時間枠:Up to 30 days post infusion
|
Measured as the proportion of patients with acute (a) graft versus host disease (GvHD) grades III-IV or graft rejection/failure within 30 days of the last dose of cytotoxic T-lymphocytes (CTLs) or grades 3-5 infusion-related adverse events within 7 days of the last does of CTLs or grades 4-5 non-hematological adverse events within 30 days of the last dose of CTLs and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities. Will be calculated by dividing by all evaluable patients and the corresponding 95% confidence intervals will be calculated. |
Up to 30 days post infusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
T細胞遺伝子再構成によって測定される注入されたCTLの持続性とウイルス感染の臨床徴候への影響
時間枠:最長1年
|
最長1年
|
|
|
毎週の逆転写酵素 - ポリメラーゼ連鎖反応によって評価されたウイルス負荷に対するサイトメガロウイルス(CMV)特異的CTLの効果
時間枠:最長1年
|
最長1年
|
|
|
CTL注入に対する臨床反応
時間枠:6週3ヶ月の時
|
6週3ヶ月の時
|
|
|
CTCAE v4.0 によって評価された、治療関連の有害事象のある参加者の数」。
時間枠:最長1年
|
最長1年
|
|
|
Antiviral activity defined as response to viral load
時間枠:At day 28
|
Complete response, partial response, stable disease or progression will be defined and proportion of each outcome will be calculated. |
At day 28
|
|
Overall survival
時間枠:From last CTL infusion till death, assessed at 6 and 12 months
|
Kaplan-Meier survival function will be used to estimate the survival probability. |
From last CTL infusion till death, assessed at 6 and 12 months
|
|
Risk for chronic GVHD
時間枠:At 6 and 12 months post CTL infusion
|
Survival analysis method will be applied. Time to chronic GVHD will be defined from time of the last CTL infusion to the onset of chronic GVHD, or the last clinical assessment date if no chronic GVHD. Cumulative incidence of chronic GVHD at 6 and 12 months will be estimated. |
At 6 and 12 months post CTL infusion
|
|
Systemic infections
時間枠:Within 6 months of CTL infusion
|
Will be reported by etiologic agent, site of disease, date of onset, and severity. |
Within 6 months of CTL infusion
|
|
Secondary graft failure
時間枠:30 days post-CTL infusion
|
Proportion of secondary graft failure for both populations will be assessed at 30 days post CTL infusion will be calculated and 95% confidence intervals will be estimated accordingly. |
30 days post-CTL infusion
|
|
Viral reactivations
時間枠:Up to 6 months
|
Proportion of viral reactivations within 6 months will be calculated and 95% confidence intervals will be estimated accordingly. |
Up to 6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sumithira Vasu, MBBS、Ohio State University Comprehensive Cancer Center
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- OSU-17199
- NCI-2018-01412 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。